Read More Pharma Industry News Why Lunit’s AACR 2026 showcase could reshape how investors value AI-driven precision oncology platforms like KRX: 328130 Lunit’s AACR 2026 studies reveal how its cancer AI platform is moving beyond pathology into biomarker strategy. Read what this means for KRX: 328130. bySrinathApril 20, 2026